All News #Library
Biotech
Kynexis Announces 1st Patient Dosed in Phase 2 Trial of KYN-5356
30 Sep 2025 //
GLOBENEWSWIRE
Kynexis Announces Results for KYN-5356 in Cognitive Impairment
17 Dec 2024 //
GLOBENEWSWIRE
Kynexis Appoints SAB For Brain Disease Precision Therapeutics
29 May 2024 //
GLOBENEWSWIRE

Market Place
Sourcing Support